Resources

The advanced HelitraxSM System is
true, wireless, mobile technology designed to strengthen the connection between
you, your patients, and their Helixate® FS therapy. This
one-of-a-kind data management system enables you and your patients to improve
the overall management of their disease…working together as a team.
In addition to the benefits of proven efficacy and safety, patients on Helixate®
FS can now have a friendlier experience managing their therapy with the new
HelitraxSM System.1–4
You and your patients stay in touch
-
True wireless, Internet-based electronic diary makes data entry easy and offers
patients the peace of mind that comes with a dependable connection to their HTC
team
-
Data compiled in one report for a clear, clinical snapshot of your patient
Treatment stays on track
-
Access to patient data before and between visits enables you to address any
complications or concerns patients may have with treatment
-
Emergency bleeding events can be rapidly assessed with high-priority messaging
and picture-taking capabilities
Closer to improved patient care with a comprehensive view of your patient’s
clinical picture
-
Continuous tracking of medication usage, inventory, bleeding events, and
follow-up—all graphically displayed in one report
-
Clinical assessment of your patient—before and between visits
-
Rapid assessment of bleeding events anywhere and at any time with built-in
camera feature
– Sends a high-priority message directly to your treatment center
in emergency bleeding event situations
– Describes in detail the specifics of a bleeding event, complete
with location, symptoms, and picture
Closer to the data management needs of your treatment center
-
Reduces the chance of documentation and transcription errors
-
Saves time by eliminating paperwork and directing only high-priority messages
to your attention
-
Provides a JACHO-compliant progress report for patient’s medical records
For more information about the HelitraxSM
System, please call CSL Behring Consumer Affairs at 1-888-508-6978.
-
1. Kreuz W, Gill JC, Rothschild C, et al, and the International Kogenate-FS
Study Group. Full-length sucrose-formulated recombinant factor VIII for
treatment of previously untreated or minimally treated young children with
severe haemophilia A: results of an international clinical investigation. Thromb
Haemost. 2005;93:457–467.
-
2. Oldenburg J, Ivaskevicius V, Schröder J, Müller CR, Ganguly A. Genetic
background and inhibitors in previously untreated or minimally treated young
patients with severe haemophilia A treated with sucrose-formulated recombinant
factor VIII. Thromb Haemost. 2006;95:903–905.
-
3. Abshire TC, Brackmann H-H,Scharrer I, et al, and the International
Kogenate-FS Study Group. Sucrose formulated recombinant human antihemophilic
factor VIII is safe and efficacious for treatment of hemophilia A in home
therapy: results of a multicenter, international, clinical investigation. Thromb
Haemost. 2000;83:811–816.
-
4. Data on file, Bayer Corporation.